Pyxis Oncology (PYXS) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $237.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | VCRE |
|---|---|---|
| Share price | $1.99 | $8.82 |
| Market cap | $237.72M | $248.41M |
| 1-day change | -1.00% | +1.85% |
| YTD return | +73.04% | — |
| 1-year return | -31.62% | — |
| 5-year return | -83.09% | — |
| EPS (TTM) | $-1.40 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $17.80 |
| 52-week low | $1.03 | $7.88 |
| Distance from 52-week high | -64.14% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +335.68% | +275.96% |
| Average volume | 1.26M | 16.22K |
| Shares outstanding | 119.46M | 28.16M |
| Employees | 56 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
PYXS vs VCRE FAQ
Which is bigger, Pyxis Oncology or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $237.72M for Pyxis Oncology (PYXS).
Are Pyxis Oncology and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.